Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamide SCHEMBL27827170 | 0.85 | TSHR (0.43) | POLBL3MBTL1KDM4EGAAPKM | |
| SCHEMBL17469085 | 0.85 | PKM (0.39) | POLBKDM4EGAAPKMTSHR | |
| SCHEMBL3060859 | 0.84 | MEN1 (0.39) | POLBL3MBTL1KDM4EGAAPKM | |
| SCHEMBL5202849 | 0.84 | MAPT (0.41) | POLBKDM4EGAAPKMMEN1 | |
| SCHEMBL354031 | 0.81 | GAA (0.43) | POLBKDM4EGAAPKMMEN1 | |
| SCHEMBL25106757 | 0.80 | KDM4E (0.43) | POLBL3MBTL1KDM4ETSHRKMT2A | |
| SCHEMBL25106572 | 0.80 | SMN1; SMN2 (0.41) | POLBL3MBTL1TSHRMEN1KMT2A | |
| SCHEMBL28783815 | 0.77 | LMNA (0.39) | POLBKDM4EGAAPKMMEN1 | |
| SCHEMBL937869 | 0.77 | PKM (0.57) | POLBGAAPKMTSHRMEN1 | |
| SCHEMBL15825776 | 0.76 | ATM (0.38) | POLBL3MBTL1KDM4EGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-10160745-B2 | Piperidine and azepine derivatives as prokineticin receptor modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-25 | — | — | US | disclosed |
| US-20180009780-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3030553-B1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9790201-B2 | Piperidine and azepine derivatives as prokineticin receptor modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9512128-B2 | Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides | BAYER CROPSCIENCE AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160185752-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-30 | — | — | US | disclosed |
| US-6329372-B1 | HETEROCYCLIC AMIDE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-12-11 | — | — | US | disclosed |
| EP-1135371-A1 | BETA-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| EP-1051399-A1 | PHENYLALANINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000064864-A1 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000032575-A1 | β-ALANINE DERIVATIVES AS α4 INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999037618-A1 | PHENYLALANINE DERIVATIVES USEFUL AS PHARMACEUTICAL AGENTS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |
| US-4235995-A | BACTERIOCIDES, PARASITICIDES, HERBICIDES | ELI LILLY AND COMPANY (US) | 1980-11-25 | — | — | US | disclosed |
| US-4145554-A | BACTERICIDES, MICROBIOCIDES, HERBICIDES, PARASITICDES | ELI LILLY AND COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
| US-4066776-A | Anti-bacterial compositions containing certain 3-nitropyrazoles | ELI LILLY AND COMPANY (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160745-B2 | Piperidine and azepine derivatives as prokineticin receptor modulators | GIPR, PROKR1, PROKR2 | POLB 4358/4885L3MBTL1 4871/4885KDM4E 2884/4885 |
| US-20160185752-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | GIPR, PROKR1, PROKR2 | POLB 4345/4885L3MBTL1 4873/4885KDM4E 2910/4885 |
| US-20180009780-A1 | PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS | GIPR, PROKR1, PROKR2 | POLB 4358/4885L3MBTL1 4871/4885KDM4E 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.